NicOx Reports First Quarter 2008 Financial Results

...NTIPOLIS, France, May 14 /PRNewswire-FirstCall/ -- nicox S.A. (Eurolist: COX) today reported financial resu...of osteoarthritis. In the first quarter of 2008, nicox recorded a net loss of euro 13 million. This compa...y operational highlights - first quarter 2008 -- nicox initiated two large Ambulatory Blood Pressure Moni...

NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program

...ANTIPOLIS, France, May 6 /PRNewswire-FirstCall/ -- nicox S.A. (Euronext Paris: COX) today announced the res...sults of this study which are expected in Q3 2008. nicox and Pfizer are currently in discussions regarding ...g Pfizer's Xalacom(R) (timolol and latanoprost). nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-dr...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...rmaceuticals Inc. (Nasdaq: IDEV ) Ipsen Ltd. (Paris: IPN.PR) Nastech Pharmaceutical Co. (Nasdaq: NSTK ) Nektar Therapeutics (Nasdaq: NKTR ) nicox S.A. (Paris: NCOX) OSI Pharmaceuticals Inc. (Nasdaq: OSIP ) ProStrakan Group Plc (LSE: PSK.L) Solvay S.A. (Brussels: SVYSY) Add Altus Pharma...

NicOx in Medical Technology

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced its financial results for 2007 and provided an overview of its activities during the year. NicOx also announced today the initiation of two large Ambulatory Blood Pressure Monitoring (A...

NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis

... an attractive new option for physicians." nicox has completed a regulatory phase 3 program for nap...s of June 13, September 15 and November 24, 2008). nicox plans to submit a New Drug Application (NDA) for n...6 and 13. Further analyses are ongoing and nicox plans to disclose more detailed results at leading...

Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results

...The 303 study is also the final pivotal trial that nicox plans to include in the submission of a New Drug A...iversity Feinberg School of Medicine, who advised nicox on the design and analysis of the trial. "Meeting ...e 303 study was pre-specified. As planned, nicox will pool the blood pressure data from the three p...

NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study

... tolerability were shown by all naproxcinod doses. nicox plans to provide further details of the results at... Drug Administration (FDA) projected for mid-2009. nicox expects to have the results of a second large ABPM...ine at the University of Pennsylvania, who advised nicox on the design and analysis of the study. "The hype...

NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect

... PARIS, September 15 /PRNewswire-FirstCall/ -- nicox S.A. (Euronext Paris: COX) today announced success... pressure. In the planning of the phase 3 program, nicox had foreseen the pooling of office blood pressure ...ly distributed among the treatment groups. NOTE: nicox entered into a full-service agreement for the cond...

NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension

...TIPOLIS, France, July 24 /PRNewswire-FirstCall/ -- nicox S.A. (Euronext Paris: COX) today announced the top... releases of June 13, 2008 and November 12, 2007). nicox expects to announce the top-line efficacy results ...ed until 52 weeks for both doses of naproxcinod. nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-dr...

NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients

...TIPOLIS, France, July 22 /PRNewswire-FirstCall/ -- nicox S.A. (Euronext Paris: COX) today announced it has ...ent of Clinical Development and Medical Affairs at nicox commented: "We are very pleased to have fully enro...strength of the clinical team we have assembled at nicox and also reflects the interest of clinical centers...

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR

...POLIS, France, June 13 /PRNewswire-FirstCall/ -- nicox S.A. (Euronext Paris: COX) today announced an addi...hibiting Nitric Oxide Donator (CINOD) class, which nicox is developing for the treatment of the signs and s... a medical history of hypertension at baseline). nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product...

NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study

...NTIPOLIS, France, May 28 /PRNewswire-FirstCall/ -- nicox S.A. (Euronext Paris: COX) today announced the com...esults from this study are expected in Q4 2008 and nicox projects the filing of a New Drug Application (NDA) in mid-2009. nicox is currently in the final stages of developing nap...

NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.

...NTIPOLIS, France, May 13 /PRNewswire-FirstCall/ -- nicox S.A. (Eurolist: COX) today announced that Merck & ...treatment for patients worldwide." In July 2007, nicox announced the initiation of the first in a series ...pment of these compounds going forward. To date, nicox has received euro 19.2 million from Merck under th...

NicOx in Biological Technology

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value

SOPHIA ANTIPOLIS, France, February 26 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced its financial results for full year 2008 and provided an overview of the development and pre-commercialization activities for naproxcinod, its lead investigational drug for the...

NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance

...OLIS, France, December 2 /PRNewswire-FirstCall/ -- nicox S.A. (NYSE Euronext Paris: COX) today announced it...ssful launch of naproxcinod. As per the agreement, nicox envisages the first deliveries of significant quan... cost control in the current economic environment, nicox has ended its present API supply agreement with Ar...

NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen

...o 2 different classes of antihypertensive drugs. nicox is developing naproxcinod in late phase 3 clinical... Administration (FDA) is projected for mid-2009. nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-dr...results anticipated in 2008. Beyond naproxcinod, nicox has a pipeline containing multiple nitric oxide-do...

NicOx Reports Results for the First Three Quarters of 2008

...ugh the primary endpoint at day 28 was not met. nicox is currently discussing the rights to PF-031872...nths of 2007. For the first nine months of 2008, nicox recognized the following amounts in revenues: ...t of sales corresponds to the expenses incurred by nicox in performing research activities under the contra...

NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules

...cal ingredient (API) with Archimica in March 2008. nicox recently announced the results of the second pivot...ith osteoarthritis of the knee (the 302 study, see nicox press release of September 15th, 2008). This study...capsules, compared to 22% who prefer tablets(1). nicox chose Capsugel as an exclusive supplier following ...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... MORPHOSYS (Frankfurt, Germany: MOR) MYRIAD GENETICS INC (NASDAQ: MYGN ) nicox SA (Euronext, Paris: COX) PATTERSON COS (NASDAQ: PDCO ) PHARMACEUTICAL P... (SWX, Switzerland: CYTN) GENMAB AS (OMX Nordic Exchange Copenhagen: GEN) nicox SA (Euronext, Paris: COX) PRESTIGE BRANDS HLDGS INC (NYSE: PBH ) Q-MED A...

NicOx Announces Departure of Damian Marron for CEO Position

...NTIPOLIS, France, May 27 /PRNewswire-FirstCall/ -- nicox S.A. (Euronext Paris: COX) today announced that Da...great opportunity to lead a biotechnology company. nicox has established itself as one of Europe's leading ...ove on to the new challenge of the role of CEO." nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-dr...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)

...nome Sciences, Inc. (Nasdaq: HGSI ) Indevus Pharmaceuticals Inc. (Nasdaq: IDEV ) Ipsen Ltd. (Paris: IPN.PR) Nektar Therapeutics (Nasdaq: NKTR ) nicox S.A. (Paris: NCOX) OSI Pharmaceuticals Inc. (Nasdaq: OSIP ) ProStrakan Group Plc (LSE: PSK.L) Solvay S.A. (Brussels: SVYSY) Add Altus Pharmaceut...

NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance

...SOPHIA ANTIPOLIS, France, March 19 /PRNewswire/ -- nicox S.A. (Euronext Paris: COX) today announced it has ...oducing APIs for the U.S. and other major markets, nicox is in a strong position to prepare the regulatory ...upply chain for naproxcinod. As per the agreement, nicox envisages the first deliveries of significant quan...

NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis

...TIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- nicox S.A. (Euronext Paris: COX) today announced the ini...0:00 pm and every hour from 10:01 pm to 5:59 am. nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product...results anticipated in 2008. Beyond naproxcinod, nicox has a pipeline containing multiple nitric oxide- d...